Cryptosporidiosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The Cryptosporidiosis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects.

Cryptosporidiosis Pipeline Drugs Market Segmentation by Targets

The key target of the Cryptosporidiosis pipeline drugs market is Calcium Dependent Protein Kinase 1.

Cryptosporidiosis Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanism of actions of the Cryptosporidiosis pipeline drugs market is Calcium Dependent Protein Kinase 1 Inhibitor.

Cryptosporidiosis Pipeline Drugs Market Segmentation by Routes of Administration

The key route of administration in the Cryptosporidiosis pipeline drugs market is oral.

Cryptosporidiosis Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Cryptosporidiosis pipeline drugs market are small molecule, recombinant vector vaccine, and antibody.

Cryptosporidiosis Pipeline Drugs Market Analysis, by Molecule Types

Cryptosporidiosis Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Cryptosporidiosis pipeline drugs market, download a free report sample

Competitive Landscape

Some of the leading companies in the Cryptosporidiosis pipeline drugs market are Aviex Technologies LLC, Novartis AG, AbbVie Inc, Epichem Pty Ltd, ImmuniMed Inc, ioGenetics Inc, Oblita Therapeutics BVBA, and PGTx Ltd.

Cryptosporidiosis Pipeline Drugs Market Analysis, by Companies

Cryptosporidiosis Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the Cryptosporidiosis pipeline drugs market, download a free report sample

Cryptosporidiosis Pipeline Drugs Market Report Overview

Key Targets Calcium Dependent Protein Kinase 1
Key Mechanism of Actions Calcium Dependent Protein Kinase 1 Inhibitor
Key Routes of Administration Oral
Key Molecule Types Small Molecule, Recombinant Vector Vaccine, and Antibody
Leading Companies Aviex Technologies LLC, Novartis AG, AbbVie Inc, Epichem Pty Ltd, ImmuniMed Inc, ioGenetics Inc, Oblita Therapeutics BVBA, and PGTx Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Cryptosporidiosis (Infectious Disease).
  • Reviews of pipeline therapeutics for Cryptosporidiosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Cryptosporidiosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • Evaluation of Cryptosporidiosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Cryptosporidiosis (Infectious Disease).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cryptosporidiosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cryptosporidiosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AbbVie Inc
Aviex Technologies LLC
Epichem Pty Ltd
ImmuniMed Inc
ioGenetics Inc
Novartis AG
Oblita Therapeutics BVBA
PGTx Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cryptosporidiosis – Overview

Cryptosporidiosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cryptosporidiosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cryptosporidiosis – Companies Involved in Therapeutics Development

Cryptosporidiosis – Drug Profiles

AV-0215W – Drug Profile

Product Description

Mechanism Of Action

AV-0216W – Drug Profile

Product Description

Mechanism Of Action

clofazimine – Drug Profile

Product Description

Mechanism Of Action

D-121 – Drug Profile

Product Description

Mechanism Of Action

DBAF-201 – Drug Profile

Product Description

Mechanism Of Action

EDI-048 – Drug Profile

Product Description

Mechanism Of Action

EPLAJ-1317 – Drug Profile

Product Description

Mechanism Of Action

KDU-731 – Drug Profile

Product Description

Mechanism Of Action

Polyclonal Antibodies – Drug Profile

Product Description

Mechanism Of Action

Recombinant Vector Vaccine for Protozoal Infection – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CDPK1 for Protozoal Infections – Drug Profile

Product Description

Mechanism Of Action

Cryptosporidiosis – Dormant Projects

Cryptosporidiosis – Discontinued Products

Cryptosporidiosis – Product Development Milestones

Featured News & Press Releases

Mar 14, 2018: Calibr’s repurposed drug to treat non-viral diarrhea enters into a clinical trial

Feb 14, 2018: Novartis forms alliance to develop medicines for treating infectious diarrheal disease

Nov 30, 2017: Novartis Institutes for BioMedical Research receives a grant of $1,542,000 from Bill & Melinda Gates Foundation

May 31, 2017: Progress reported in global fight against diarrheal disease cryptosporidiosis

May 01, 2017: Polyclonal antibodies used in the treatment of cryptosporidiosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Cryptosporidiosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cryptosporidiosis – Pipeline by AbbVie Inc, 2022

Cryptosporidiosis – Pipeline by Aviex Technologies LLC, 2022

Cryptosporidiosis – Pipeline by Epichem Pty Ltd, 2022

Cryptosporidiosis – Pipeline by ImmuniMed Inc, 2022

Cryptosporidiosis – Pipeline by ioGenetics Inc, 2022

Cryptosporidiosis – Pipeline by Novartis AG, 2022

Cryptosporidiosis – Pipeline by Oblita Therapeutics BVBA, 2022

Cryptosporidiosis – Pipeline by PGTx Ltd, 2022

Cryptosporidiosis – Dormant Projects, 2022

Cryptosporidiosis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Cryptosporidiosis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Cryptosporidiosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Cryptosporidiosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cryptosporidiosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Cryptosporidiosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.